zur Navigation zum Inhalt
 
Onkologie 12. Juli 2017

ASCO 2016 – update colorectal liver metastases

Summary

This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3’UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben